J Gynecol Oncol.  2011 Mar;22(1):32-38. 10.3802/jgo.2011.22.1.32.

Is human papillomavirus genotype an influencing factor on radiotherapy outcome? Ambiguity caused by an association of HPV 18 genotype and adenocarcinoma histology

• Kim JY
• Nam BH
• Lee JA

• KMID: 2173583
• DOI: http://doi.org/10.3802/jgo.2011.22.1.32

Abstract

OBJECTIVE
To evaluate whether human papillomavirus (HPV) genotype is associated with poor prognosis of uterine cervical cancer treated primarily with radiotherapy.
METHODS
HPV genotyping was performed in 181 radiotherapy patients using SPF10 polymerase chain reaction and HPV reverse hybridization line probe assay. Univariate and multivariate Cox regression analysis was performed to explore the prognostic factors. Bivariate analysis was performed to investigate any association between HPV genotype and the rest of the prognostic factors.
RESULTS
HPV type 18 was associated with poor disease-free survival on univariate analysis but the statistical significance was abolished when multivariate analysis was applied. Bivariate analysis was performed to examine the possible confounding factors influencing the effect of HPV 18 on prognosis. As a result, adeno/adenosquamous carcinoma histology reduced the prognostic importance of HPV 18 by 66% (2.4 to 1.6), and was the only factor which reduced the hazard ratio of HPV 18. When compared to non-18 squamous cell carcinoma, type 18 increased the risk of recurrence up to 4-fold in adeno/adenosquamous/HPV 18 and 3.7 in adeno/adenosquamous/non-18, and to 2-fold in squamous carcinoma/HPV 18, respectively.
CONCLUSION
Our data suggest that the prognostic significance of HPV 18 genotype is substantial on radiotherapy outcome, but can be underestimated because of the close association of the HPV 18 and adenocarcinoma/adenosquamous carcinoma histology. Both HPV 18 and histologic type should be regarded as strong prognostic factors in considering the treatment outcome of the uterine cervical cancer.

Keyword

Human papillomavirus 18; Adenocarcinoma; Adenosquamous carcinoma; Uterine cervical cancer; Radiotherapy outcome

MeSH Terms

Adenocarcinoma
Carcinoma, Adenosquamous
Carcinoma, Squamous Cell
Chimera
Disease-Free Survival
Genotype
Human papillomavirus 18
Humans
Multivariate Analysis
Polymerase Chain Reaction
Prognosis
Recurrence
Treatment Outcome
Uterine Cervical Neoplasms

Figure

• 

  Fig. 1 Disease-free survival (DFS) by HPV type (A) and histologic types (B). HPV: human papillomavirus, SCC: squamous cell carcinoma, AD/ASC: adenocarcinoma/adenosquamous carcinoma.

• 

  Fig. 2 Disease-free survival in 4 histology/HPV18 combined groups. SCC: squamous cell carcinoma, AD/ASC: adenocarcinoma/adenosquamous carcinoma, HPV: human papillomavirus.

Reference

1. Burger RA, Monk BJ, Kurosaki T, Anton-Culver H, Vasilev SA, Berman ML, et al. Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer. J Natl Cancer Inst. 1996. 88:1361–1368.

2. Fujiwara H, Mitchell MF, Arseneau J, Hale RJ, Wright TC Jr. Clear cell adenosquamous carcinoma of the cervix: an aggressive tumor associated with human papillomavirus-18. Cancer. 1995. 76:1591–1600.

3. Kitagawa K, Yoshikawa H, Onda T, Kawana T, Taketani Y, Yoshikura H, et al. Genomic organization of human papillomavirus type 18 in cervical cancer specimens. Jpn J Cancer Res. 1996. 87:263–268.

4. Lai CH, Chang CJ, Huang HJ, Hsueh S, Chao A, Yang JE, et al. Role of human papillomavirus genotype in prognosis of early-stage cervical cancer undergoing primary surgery. J Clin Oncol. 2007. 25:3628–3634.

5. Lombard I, Vincent-Salomon A, Validire P, Zafrani B, de la Rochefordiere A, Clough K, et al. Human papillomavirus genotype as a major determinant of the course of cervical cancer. J Clin Oncol. 1998. 16:2613–2619.

6. Im SS, Wilczynski SP, Burger RA, Monk BJ. Early stage cervical cancers containing human papillomavirus type 18 DNA have more nodal metastasis and deeper stromal invasion. Clin Cancer Res. 2003. 9:4145–4150.

7. Kim JY, Park S, Nam BH, Roh JW, Lee CH, Kim YH, et al. Low initial human papilloma viral load implicates worse prognosis in patients with uterine cervical cancer treated with radiotherapy. J Clin Oncol. 2009. 27:5088–5093.

8. Andersson S, Rylander E, Larson B, Sigurdardottir S, Backlund I, Sallstrom J, et al. Types of human papillomavirus revealed in cervical adenocarcinomas after DNA sequencing. Oncol Rep. 2003. 10:175–179.

9. Iwasawa A, Nieminen P, Lehtinen M, Paavonen J. Human papillomavirus DNA in uterine cervix squamous cell carcinoma and adenocarcinoma detected by polymerase chain reaction. Cancer. 1996. 77:2275–2279.

10. Schellekens MC, Dijkman A, Aziz MF, Siregar B, Cornain S, Kolkman-Uljee S, et al. Prevalence of single and multiple HPV types in cervical carcinomas in Jakarta, Indonesia. Gynecol Oncol. 2004. 93:49–53.

11. Tase T, Okagaki T, Clark BA, Manias DA, Ostrow RS, Twiggs LB, et al. Human papillomavirus types and localization in adenocarcinoma and adenosquamous carcinoma of the uterine cervix: a study by in situ DNA hybridization. Cancer Res. 1988. 48:993–998.

12. Tase T, Sato S, Wada Y, Yajima A, Okagaki T. Prevalence of human papillomavirus type 18 DNA in adenocarcinoma and adenosquamous carcinoma of the uterine cervix occurring in Japan. Tohoku J Exp Med. 1988. 156:47–53.

13. Teshima H, Beaudenon S, Koi S, Katase K, Hasumi K, Masubuchi K, et al. Human papillomavirus type 18 DNA sequences in adenocarcinoma and adenosquamous carcinoma of the uterine cervix. Arch Gynecol Obstet. 1997. 259:169–177.

14. Uchiyama M, Iwasaka T, Matsuo N, Hachisuga T, Mori M, Sugimori H. Correlation between human papillomavirus positivity and p53 gene overexpression in adenocarcinoma of the uterine cervix. Gynecol Oncol. 1997. 65:23–29.

15. Yamakawa Y, Forslund O, Teshima H, Hasumi K, Kitagawa T, Hansson BG. Human papillomavirus DNA in adenocarcinoma and adenosquamous carcinoma of the uterine cervix detected by polymerase chain reaction (PCR). Gynecol Oncol. 1994. 53:190–195.

16. Yoshida T, Sano T, Oyama T, Kanuma T, Fukuda T. Prevalence, viral load, and physical status of HPV 16 and 18 in cervical adenosquamous carcinoma. Virchows Arch. 2009. 455:253–259.

17. Reimers LL, Anderson WF, Rosenberg PS, Henson DE, Castle PE. Etiologic heterogeneity for cervical carcinoma by histopathologic type, using comparative age-period-cohort models. Cancer Epidemiol Biomarkers Prev. 2009. 18:792–800.

18. Saint-Paul MT, Brémond A, Rochet Y. Cervical cancer before 35 years of age: epidemiological and prognostic aspects. Retrospective study of 46 cases of cervical cancer before 35 years of age in a series of 449 cases in stages IA2 and IV. J Gynecol Obstet Biol Reprod (Paris). 1993. 22:737–742.

19. Barnes W, Delgado G, Kurman RJ, Petrilli ES, Smith DM, Ahmed S, et al. Possible prognostic significance of human papillomavirus type in cervical cancer. Gynecol Oncol. 1988. 29:267–273.

20. Ogura K, Ishi K, Matsumoto T, Kina K, Nojima M, Suda K. Human papillomavirus localization in cervical adenocarcinoma and adenosquamous carcinoma using in situ polymerase chain reaction: review of the literature of human papillomavirus detection in these carcinomas. Pathol Int. 2006. 56:301–308.

21. Lee MF, Chang MC, Wu CH. Detection of human papillomavirus types in cervical adenocarcinoma by the polymerase chain reaction. Int J Gynaecol Obstet. 1998. 63:265–270.

22. Liebrich C, Brummer O, Von Wasielewski R, Wegener G, Meijer C, Iftner T, et al. Primary cervical cancer truly negative for high-risk human papillomavirus is a rare but distinct entity that can affect virgins and young adolescents. Eur J Gynaecol Oncol. 2009. 30:45–48.

23. Botezatu A, Socolov D, Goia CD, Iancu IV, Ungureanu C, Huica I, et al. The relationship between HPV16 and HPV 18 viral load and cervical lesions progression. Roum Arch Microbiol Immunol. 2009. 68:175–182.

24. Castellsague X, Diaz M, de Sanjose S, Munoz N, Herrero R, Franceschi S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst. 2006. 98:303–315.

25. Hildesheim A, Berrington de Gonzalez A. Etiology and prevention of cervical adenocarcinomas. J Natl Cancer Inst. 2006. 98:292–293.

26. Wheeler CM, Hunt WC, Joste NE, Key CR, Quint WG, Castle PE. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst. 2009. 101:475–487.

27. Eifel PJ, Burke TW, Delclos L, Wharton JT, Oswald MJ. Early stage I adenocarcinoma of the uterine cervix: treatment results in patients with tumors less than or equal to 4 cm in diameter. Gynecol Oncol. 1991. 41:199–205.

28. Eifel PJ, Burke TW, Morris M, Smith TL. Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma. Gynecol Oncol. 1995. 59:38–44.

29. Eifel PJ, Morris M, Oswald MJ, Wharton JT, Delclos L. Adenocarcinoma of the uterine cervix: prognosis and patterns of failure in 367 cases. Cancer. 1990. 65:2507–2514.

30. Kjorstad KE, Bond B. Stage IB adenocarcinoma of the cervix: metastatic potential and patterns of dissemination. Am J Obstet Gynecol. 1984. 150:297–299.

31. Kosary CL. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol. 1994. 10:31–46.

32. Lea JS, Sheets EE, Wenham RM, Duska LR, Coleman RL, Miller DS, et al. Stage IIB-IVB cervical adenocarcinoma: prognostic factors and survival. Gynecol Oncol. 2002. 84:115–119.

33. Matthews CM, Burke TW, Tornos C, Eifel PJ, Atkinson EN, Stringer CA, et al. Stage I cervical adenocarcinoma: prognostic evaluation of surgically treated patients. Gynecol Oncol. 1993. 49:19–23.

34. Nakanishi T, Ishikawa H, Suzuki Y, Inoue T, Nakamura S, Kuzuya K. A comparison of prognoses of pathologic stage Ib adenocarcinoma and squamous cell carcinoma of the uterine cervix. Gynecol Oncol. 2000. 79:289–293.

35. Reagan JW, Fu YS. Histologic types and prognosis of cancers of the uterine cervix. Int J Radiat Oncol Biol Phys. 1979. 5:1015–1020.

36. Recoules-Arche A, Rouzier R, Rey A, Villefranque V, Haie-Meder C, Pautier P, et al. Does adenocarcinoma of uterine cervix have a worse prognosis than squamous carcinoma? Gynecol Obstet Fertil. 2004. 32:116–121.

37. Samlal RA, van der Velden J, Ten Kate FJ, Schilthuis MS, Hart AA, Lammes FB. Surgical pathologic factors that predict recurrence in stage IB and IIA cervical carcinoma patients with negative pelvic lymph nodes. Cancer. 1997. 80:1234–1240.

38. Farley JH, Hickey KW, Carlson JW, Rose GS, Kost ER, Harrison TA. Adenosquamous histology predicts a poor outcome for patients with advanced-stage, but not early-stage, cervical carcinoma. Cancer. 2003. 97:2196–2202.